 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Dialysis |
* Fresenius Medical Care North America, Lexington, the Renal Unit and Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts
Address correspondence to: Dr. Ravi Thadhani, Bullfinch 127, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114. Phone: 617-724-1207; Fax: 617-726-2340; E-mail: thadhani.r{at}mgh.harvard.edu
Received for publication July 20, 2004. Accepted for publication January 17, 2005.
Patients with ESRD commonly experience secondary hyperparathyroidism, a condition primarily managed with activated injectable vitamin D. The biologic effects of vitamin D, however, are widespread, and it is possible that activated injectable vitamin D alters survival in ESRD. This hypothesis was tested in a historical cohort study of incident hemodialysis patients who lived throughout the United States between January 1996 and December 1999. The primary outcome was 2-yr survival among those who survived for at least 90 d after initiation of chronic hemodialysis. During this period, 51,037 chronic hemodialysis patients survived for at least 90 d from the initiation of hemodialysis, and in the ensuing 2 yr, 37,173 received activated injectable vitamin D and 13,864 did not. At 2 yr, mortality rates were 13.8/100 person-years in the group that received injectable vitamin D compared with 28.6/100 person-years in the group that did not (P < 0.001). Cox proportional hazards analyses adjusting for several potential confounders and examining injectable vitamin D therapy as a time-dependent exposure suggested that compared with patients who did not receive injectable vitamin D, the 2-yr survival advantage associated with the group that did receive injectable vitamin D was 20% (hazard ratio, 0.80; 95% confidence interval, 0.76 to 0.83). The incidence of cardiovascular-related mortality was 7.6/100 person-years in the injectable vitamin D group, compared with 14.6/100 person-years in the non–vitamin D group (P < 0.001). The benefit of injectable vitamin D was evident in 48 of 49 strata examined, including those with low serum levels of intact parathyroid hormone and elevated levels of serum calcium and phosphorus, situations in which injectable vitamin D is often withheld. Repeating the entire analysis using marginal structural models to adjust for time-dependent confounding by indication yielded a survival advantage of 26% (hazard ratio, 0.74; 95% confidence interval, 0.71 to 0.79) associated with the injectable vitamin D group. In this historical cohort study, chronic hemodialysis patients in the group that received injectable vitamin D had a significant survival advantage over patients who did not. Randomized clinical trials would permit definitive conclusions.
This article has been cited by other articles:
 |
|
 |
|
  W. Noonan, K. Koch, M. Nakane, J. Ma, D. Dixon, A. Bolin, and G. Reinhart Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3824 - 3830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tentori, J. M. Albert, E. W. Young, M. J. Blayney, B. M. Robinson, R. L. Pisoni, T. Akiba, R. N. Greenwood, N. Kimata, N. W. Levin, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study Nephrol. Dial. Transplant., November 21, 2008; (2008) gfn592v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Covic, P. Kothawala, M. Bernal, S. Robbins, A. Chalian, and D. Goldsmith Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease Nephrol. Dial. Transplant., November 11, 2008; (2008) gfn613v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Negri Association of oral calcitriol with improved survival in non-dialyzed and dialyzed patients with CKD Nephrol. Dial. Transplant., November 7, 2008; (2008) gfn624v1. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Shinaberger, J. D. Kopple, C. P. Kovesdy, C. J. McAllister, D. van Wyck, S. Greenland, and K. Kalantar-Zadeh Ratio of Paricalcitol Dosage to Serum Parathyroid Hormone Level and Survival in Maintenance Hemodialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1769 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Regidor, C. P. Kovesdy, R. Mehrotra, M. Rambod, J. Jing, C. J. McAllister, D. Van Wyck, J. D. Kopple, and K. Kalantar-Zadeh Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2193 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Koleganova, G. Piecha, E. Ritz, and M.-L. Gross Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats Nephrol. Dial. Transplant., October 1, 2008; (2008) gfn549v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Wallis, S. Penckofer, and G. W. Sizemore The "Sunshine Deficit" and Cardiovascular Disease Circulation, September 30, 2008; 118(14): 1476 - 1485. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Matias, C. Ferreira, C. Jorge, M. Borges, I. Aires, T. Amaral, C. Gil, J. Cortez, and A. Ferreira 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients Nephrol. Dial. Transplant., September 4, 2008; (2008) gfn502v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Vervloet and J. W. R. Twisk Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data Nephrol. Dial. Transplant., September 3, 2008; (2008) gfn492v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Al-Badr and K. J. Martin Vitamin D and Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1555 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Danese, V. Belozeroff, K. Smirnakis, and K. J. Rothman Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1423 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ritz Nephrology Potpourri Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1253 - 1259. [Full Text] [PDF]
|
|
|
|
|
|
X. Tan, X. Wen, and Y. Liu Paricalcitol Inhibits Renal Inflammation by Promoting Vitamin D Receptor-Mediated Sequestration of NF-{kappa}B Signaling J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1741 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Melamed, E. D. Michos, W. Post, and B. Astor 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General Population Arch Intern Med, August 11, 2008; 168(15): 1629 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Gutierrez, M. Mannstadt, T. Isakova, J. A. Rauh-Hain, H. Tamez, A. Shah, K. Smith, H. Lee, R. Thadhani, H. Juppner, et al. Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis N. Engl. J. Med., August 7, 2008; 359(6): 584 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mathew, R. J. Lund, L. R. Chaudhary, T. Geurs, and K. A. Hruska Vitamin D Receptor Activators Can Protect against Vascular Calcification J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1509 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Shoben, K. D. Rudser, I. H. de Boer, B. Young, and B. Kestenbaum Association of Oral Calcitriol with Improved Survival in Nondialyzed CKD J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1613 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wolf Active Vitamin D and Survival J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1442 - 1443. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Block, S. Zeig, J. Sugihara, G. M. Chertow, E. M. Chi, S. A. Turner, D. A. Bushinsky, and for the TARGET Investigators Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2311 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wolf, J. Betancourt, Y. Chang, A. Shah, M. Teng, H. Tamez, O. Gutierrez, C. A. Camargo Jr., M. Melamed, K. Norris, et al. Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1379 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. How, D. L. Mason, and A. H. Lau Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213. [Abstract] [PDF]
|
|
|
|
|
|
A. B. Pai and T. A. Conner Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D Journal of Pharmacy Practice, June 1, 2008; 21(3): 214 - 224. [Abstract] [PDF]
|
|
|
|
 |
|
 V. M. Brandenburg and J. Floege Adynamic bone disease--bone and beyond NDT Plus, June 1, 2008; 1(3): 135 - 147. [Full Text] [PDF]
|
|
|
|
|
|
R. Shroff, M. Egerton, M. Bridel, V. Shah, A. E. Donald, T. J. Cole, M. P. Hiorns, J. E. Deanfield, and L. Rees A Bimodal Association of Vitamin D Levels and Vascular Disease in Children on Dialysis J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raggi and M. Kleerekoper Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 836 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Brunelli, M. M. Joffe, R. K. Israni, W. Yang, S. Fishbane, J. S. Berns, and H. I. Feldman History-Adjusted Marginal Structural Analysis of the Association between Hemoglobin Variability and Mortality among Chronic Hemodialysis Patients Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 777 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Kovesdy, S. Ahmadzadeh, J. E. Anderson, and K. Kalantar-Zadeh Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease Arch Intern Med, February 25, 2008; 168(4): 397 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ferreira, J. M. Frazao, M.-C. Monier-Faugere, C. Gil, J. Galvao, C. Oliveira, J. Baldaia, I. Rodrigues, C. Santos, S. Ribeiro, et al. Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients J. Am. Soc. Nephrol., February 1, 2008; 19(2): 405 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Kovesdy, R. Mehrotra, and K. Kalantar-Zadeh Battleground: Chronic Kidney Disorders Mineral and Bone Disease Calcium Obsession, Vitamin D, and Binder Confusion Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 168 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Andress Bone and Mineral Guidelines for Patients with Chronic Kidney Disease: A Call for Revision Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 179 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bushinsky and P. Messa Efficacy of Early Treatment with Calcimimetics in Combination with Reduced Doses of Vitamin D Sterols in Dialysis Patients NDT Plus, January 1, 2008; 1(suppl_1): i18 - i23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Palmer, D. O. McGregor, P. Macaskill, J. C. Craig, G. J. Elder, and G. F.M. Strippoli Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease Ann Intern Med, December 18, 2007; 147(12): 840 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun Ann Intern Med, December 18, 2007; 147(12): 880 - 881. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saab, A. T. Whaley-Connell, R. Khanna, and J. R. Sowers Review: Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 107 - 112. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Spiegel, P. Raggi, G. Smits, and G. A. Block Factors associated with mortality in patients new to haemodialysis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3568 - 3572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ray, W. J. Valentine, and A. J. Palmer Cost utility analysis of cinacalcet in addition to standard of care in the UK Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3355 - 3357. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wu-Wong, M. Nakane, J. Ma, X. Ruan, and P. E. Kroeger Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1592 - F1604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bodyak, J. C. Ayus, S. Achinger, V. Shivalingappa, Q. Ke, Y.-S. Chen, D. L. Rigor, I. Stillman, H. Tamez, P. E. Kroeger, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals PNAS, October 23, 2007; 104(43): 16810 - 16815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Stubbs, S. Liu, W. Tang, J. Zhou, Y. Wang, X. Yao, and L. D. Quarles Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2116 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rashid, J. Bernheim, J. Green, and S. Benchetrit Cardiovascular Events and Parathyroid Hormone--Suggestion of a Further Link J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1023 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Martin and E. A. Gonzalez Metabolic Bone Disease in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Michos and R. S. Blumenthal Vitamin D Supplementation and Cardiovascular Disease Risk Circulation, February 20, 2007; 115(7): 827 - 828. [Full Text] [PDF]
|
|
|
|
|
|
G. M. London, A. P. Guerin, F. H. Verbeke, B. Pannier, P. Boutouyrie, S. J. Marchais, and F. Metivier Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency J. Am. Soc. Nephrol., February 1, 2007; 18(2): 613 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Cannata-Andia, M. Rodriguez-Garcia, N. Carrillo-Lopez, M. Naves-Diaz, and B. Diaz-Lopez Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S267 - S273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.T. Liu, S. Stenger, H. Li, L. Wenzel, B.H. Tan, S.R. Krutzik, M.T. Ochoa, J. Schauber, K. Wu, C. Meinken, et al. Vitamin D3-Triggered Antimicrobial Response--Another Pleiotropic Effect beyond Mineral and Bone Metabolism: Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response. Science 311: 1770-1773, 2006 J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2949 - 2953. [Full Text] [PDF]
|
|
|
|
 |
|
 V. C Dennis and G. L Albertson Doxercalciferol Treatment of Secondary Hyperparathyroidism Ann. Pharmacother., November 1, 2006; 40(11): 1955 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Reichel Reply Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2989 - 2990. [Full Text] [PDF]
|
|
|
|
|
|
M. Noordzij, J. C. Korevaar, W. J. Bos, E. W. Boeschoten, F. W. Dekker, P. M. Bossuyt, R. T. Krediet, and for the NECOSAD Study Group Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2513 - 2520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Thadhani and M. Tonelli Cohort Studies: Marching Forward Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1117 - 1123. [Full Text] [PDF]
|
|
|
|
|
|
J. Q Hudson Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies Ann. Pharmacother., September 1, 2006; 40(9): 1584 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wu-Wong, W. Noonan, J. Ma, D. Dixon, M. Nakane, A. L. Bolin, K. A. Koch, S. Postl, S. J. Morgan, and G. A. Reinhart Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Regidor, J. D. Kopple, C. P. Kovesdy, R. D. Kilpatrick, C. J. McAllister, J. Aronovitz, S. Greenland, and K. Kalantar-Zadeh Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1181 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Chertow, S. Blumenthal, S. Turner, M. Roppolo, L. Stern, E. M. Chi, J. Reed, and on behalf of the CONTROL Investigators Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 305 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kalantar-Zadeh, D. L. Regidor, C. J. McAllister, B. Michael, and D. G. Warnock Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3070 - 3080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gutierrez, T. Isakova, E. Rhee, A. Shah, J. Holmes, G. Collerone, H. Juppner, and M. Wolf Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2205 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
